Scholar Rock Holding Corporation Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress

Scholar Rock Holding Corporation (SRRK) discussed the resubmission of its Biologics License Application (BLA) for apitegromab in spinal muscular atrophy (SMA) and regulatory progress. The company is awaiting FDA feedback on the resubmission, which is expected in the second half of 2023. Scholar Rock is also working on the BLA for its treatment for Duchenne muscular dystrophy (DMD). The company plans to provide an update on the BLA for DMD in the first half of 2023.